Chronic lymphocytic leukemia (CLL) has one of the highest familial risks of any cancer, with first-degree relatives having an 8.5-fold increase in their risk of the disease [Citation1]. CLL families are defined as having two or more blood-related family members with CLL, and a familial CLL case is a person with a blood-related relative with CLL. The genetic basis of familial CLL is not yet fully defined. Currently, 25 inherited genetic variants have been identified to be associated with risk of CLL through well-designed genome-wide association studies [Citation2]. These genetic variants are common, with allele frequencies greater than 5%. A number of these variants are mapped in or near genes involved in apoptosis, a key biological pathway. Although these variants themselves do not cause CLL, they provide direction for future functional studies. Taken together, these variants explain ˜ 17% of the genetic heritability of incident CLL, and mathematical models suggest that more genetically related variants are yet to be identified with larger studies or studies using newer technology. These genetic variants may include rare variants, epigenomic changes or structural variants. Of interest, the currently known 25 variants are associated with CLL risk regardless of the familial status of the CLL cases. That is, familial CLL cases improve the ability to locate the genetic variants but the known genetic variants are not specific to familial CLL risk. As a result, the population risk of CLL reflects a major genetic component rather than an environmental one, given the limited evidence for a role for environmental factors in CLL risk.
In this issue of Leukemia and Lymphoma, Mak et al. [Citation3] report their incidence findings of CLL in people of Chinese descent living in the Canadian province of British Columbia (BC) and Hong Kong during the period 1983–2008. It is well known that CLL incidence varies by ethnicity, with the highest incidence seen in individuals of European descent and the lowest rate among Asians [Citation4]. Prior migration studies [Citation5,Citation6] have shown that Asians retain the lower CLL incidence rates characteristic of their country of origin when they migrate to the West. The study by Mak et al. supports these findings using two population-based cancer registries and census data from BC and Hong Kong. The authors identified all cases of CLL in these regions during the period of investigation. The ethnicity of the Chinese BC cases was verified from individual patient charts. The number of individuals with CLL who were non-Chinese BC, Chinese BC or Hong Kong cases were compared to their respective census data, resulting in clear differences in incidence between the Chinese and non-Chinese populations and a similarity of incidence between the BC-Chinese and HK-Chinese populations.
The validity of these conclusions could be limited because of structural problems with this study. A minor concern is that the authors did not specify what ethnic groups were included in the non-Chinese BC cases of CLL, but given the ethnic distribution of BC, a majority would be expected to be of European descent. Of greater concern is the authors’ failure to consider the several major changes in the methods of detection and diagnostic definitions of CLL during the period of investigation of their study. The current definition of CLL as the presence of a circulating clonal population of B-cell lymphocytes of more than 5 × 109 cells/L that have a characteristic immunophenotype [Citation7] dates to 2008, and would thus not have been used for the majority of cases reported in this study. The changes in diagnostic methods and criteria for CLL are the most likely cause for the apparent increase in the incidence of CLL over time, regardless of ethnic group or age group in this study, which is likely erroneous. Although this is a major flaw of the manuscript, it does not detract from the take-home message of supporting a strong genetic component to the risk of CLL for all patients with the disease.
Supplementary Material
Download Zip (2.2 MB)Potential conflict of interest
A disclosure form provided by the author is available with the full text of this article at www.informahealthcare.com/lal.
References
- Goldin LR, Bjorkholm M, Kristinsson SY, et al. Elevated risk of chronic lymphocytic leukemia and other indolent non-Hodgkin's lymphomas among relatives of patients with chronic lymphocytic leukemia. Haematologica 2009;94:647–653.
- Berndt SI, Skibola CF, Joseph V, et al. Genome-wide association study identifies multiple risk loci for chronic lymphocytic leukemia. Nat Genet 2013;45:868–876.
- Mak V, Ip D, Mang O, et al. Preservation of lower incidence of chronic lymphocytic leukemia in Chinese residents in British Columbia: a 26-year survey from 1983 to 2008. Leuk Lymphoma 2014;55:824–827.
- Howlader N, Noone AM, Krapcho M, et al. SEER Cancer Statistics Review, 1975–2010, National Cancer Statistics Review. Bethesda: National Cancer Institute; 2012.
- Parkin DM. International variation. Oncogene 2004 23:6329–6340.
- Pang JWY, Cook LS, Schwartz SM, et al. Incidence of leukemia in Asian migrants to the United States and their descendants. Cancer Causes Control 2002;13:791–795.
- Hallek M, Cheson BD, Catovsky D, et al. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood 2008;111:5446–5456.